MSH|^~\&|LAB|SMH|||202001141347||ORU^R01|4146231|D|2.3|||AL|NE
PID|1||SM00047239|SM47017|SMITHTEST^SWITCH^B||19721111|F||||||||||SM003928/19|9874757308
OBR|1|37943^LAB|00028595^1401:H00007R^LAB^140120:H7^37943|200.1000^CBC^Hematology Cell Panel^^^XCA01592-5||202001141251|202001141250|||||||202001141250||||||||||LAB|F||||
NTE|1||***Edit to Patient Demographics***
NTE|2||Patient gender/age has been edited from 48F to 47F.
NTE|3||Reference ranges, H/L flagging and the calculated eGFR on
NTE|4||this sample may be impacted.
OBX|1|ST|200.1300^WBC^White Blood Cell (CBC)^^12227-5^26464-8|1|5.0^^Y|x10*9/L|4.0-11.0|N||A^S|F|||202001141253
OBX|2|ST|200.1700^RBC^Red Blood Cell Count^^789-8^789-8|1|3.50^^Y|x10*12/L|3.50-5.00|N||A^S|F|||202001141253
OBX|3|ST|200.1800^HB^Hemoglobin^^718-7^718-7|1|135^^Y|g/L|115-160|N||A^S|F|||202001141253
OBX|4|ST|200.2000^HCT^Hematocrit^^4544-3^4544-3|1|0.40^^Y|L/L|0.35-0.47|N||A^S|F|||202001141253
OBX|5|ST|200.2100^MCV^Mean Corpuscular Volume^^787-2^787-2|1|80^^Y|fL|80-100|N||A^S|F|||202001141253
OBX|6|ST|200.2500^PLT^Platelet Count^^777-3^777-3|1|200^^Y|x10*9/L|150-400|N||A^S|F|||202001141253
OBX|7|ST|200.3100^NE#^Absolute Neutrophils^^751-8^26499-4|1|3.0^^Y|x10*9/L|2.0-8.0|N||A^S|F|||202001141253
OBX|8|ST|200.3300^LY#^Absolute Lymphocytes^^731-0^26474-7|1|2.0^^Y|x10*9/L|1.0-4.0|N||A^S|F|||202001141253
OBX|9|ST|200.3400^MO#^Absolute Monocytes^^742-7^26484-6|1|0.5^^Y|x10*9/L|0.1-0.8|N||A^S|F|||202001141253

MSH|^~\&|LAB|SMH|||202001141347||ORU^R01|4146232|D|2.3|||AL|NE
PID|1||SM00047239|SM47017|SMITHTEST^SWITCH^B||19721111|F||||||||||SM003928/19|9874757308
OBR|1|37944^LAB|00028595^1401:HC00003R^LAB^140120:HC3^37944|220.8900^INR^INR^^^6301-6||202001141251|202001141250|||||||202001141250||||||||||LAB|F||||
NTE|1||***Edit to Patient Demographics***
NTE|2||Patient gender/age has been edited from 48F to 47F.
NTE|3||Reference ranges, H/L flagging and the calculated eGFR on
NTE|4||this sample may be impacted.
OBX|1|ST|220.9000^INR R^INR^^6301-6^6301-6|1|1.5^^Y||0.8-1.2|H||A^S|F|||202001141252
NTE|1||INR Therapeutic Ranges:
NTE|2||    Mechanical Heart Valves 2.5 - 3.5
NTE|3||    Other indications       2.0 - 3.0

MSH|^~\&|MIC|SMH|||202001141347||ORU^R01|4146233|D|2.3|||AL|NE
PID|1||SM00047239|SM47017|SMITHTEST^SWITCH^B||19721111|F||||||||||SM003928/19|9874757308
OBR|1|37946^MIC|00028595^20:U0000009R^MIC^20:U9^37946|500.1000^U^Urine Culture^^^630-4||202001141251|202001141250|||||||202001141250|Urine^^^Midstream urine|||||||||MB|P||||
NTE|1||***Edit to Patient Demographics***
NTE|2||Patient gender/age has been edited from 48F to 47F.
NTE|3||Reference ranges, H/L flagging and the calculated eGFR on
NTE|4||this sample may be impacted.
OBX|1|CE|500.1000^U^Urine Culture^^^630-4^O:ECOL|1.1|ECOL^Escherichia coli|||A|||P|||202001141252
OBX|2|ST|500.1000^U^Urine Culture^^^630-4^P:ORGIDSECOM|1.1|||||||P|||202001141252
OBX|3|ST|500.1000^U^Urine Culture^^^630-4^R:FSU|1.1|Further susceptibility testing underway.||||||P|||202001141252